Default company panoramic image


Identification of small molecules for the treatment of orphan genetic diseases, and their preclinical development through outsourcing

  • Stage Product In Development
  • Industry Biotechnology
  • Location Chemin de Pierrefleur, Lausanne, VD, Switzerland
  • Currency CHF
  • Founded December 2012
  • Employees 2
  • Website

Company Summary

DORPHAN is a Swiss biopharmaceutical company developing innovative medical solutions for rare diseases. The company operates by identifying, acquiring and further developing promising early stage research programs. The main objective of DORPHAN is the constitution of a portfolio of drug candidates for the treatment of orphan diseases, followed by the development of these molecules up to a deal point for out-licensing to pharmaceutical companies.


  • Default avatar
    Stephane Demotz

    Stéphane has over 20 years of professional experience gained in pharmaceutical companies and start-ups in Switzerland and abroad. He founded Edimer Biotech, which, with an investment of $25 million, led to the development of a treatment for a rare and orphan disease. As a member of the Swiss Sanfilippo Foundation, he put in place research programs in the mucopolysaccharidosis field. These activities have resulted to the founding of Dorphan.

Previous Investors

  • Default avatar
    Private investors